Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Bode

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Mediators of Inflammation|September 5, 2015
Elevated Serum Levels of Soluble TNF Receptors and Adhesion Molecules Are Associated with Diabetic Retinopathy in Patients with Type-1 DiabetesShruti Sharma, Sharad Purohit, Ashok Sharma, et al.
Diabetes Care|August 31, 2012
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trialIrl B Hirsch, Bruce Bode, Jean-Pierre Courreges, et al.
Annals of Internal Medicine|September 25, 2023
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized TrialHarpreet S Bajaj, Jens Aberle, Melanie Davies, et al.
Diabetes, Obesity & Metabolism|March 9, 2021
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2Mark Warren, Bruce Bode, Jang I Cho, et al.
Journal of Diabetes Science and Technology|April 4, 2025
Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor DesignShridhara Alva, Anuj Bhargava, Bruce Bode, et al.
The Lancet. Diabetes & Endocrinology|September 6, 2014
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetesStephen C L Gough, Bruce Bode, Vincent Woo, et al.
Diabetes Care|March 5, 2002
Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetesBruce Bode, Richard Weinstein, David Bell, et al.
The Lancet. Diabetes & Endocrinology|June 14, 2019
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trialThomas R Pieber, Bruce Bode, Ann Mertens, et al.
Lancet (London, England)|September 30, 2008
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialAlan Garber, Robert Henry, Robert Ratner, et al.
The Diabetes Educator|April 21, 2004
Patient perception and use of an insulin injector/glucose monitor combined deviceBruce Bode, John Shelmet, Brent Gooch, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Mediators of Inflammation|September 5, 2015
Elevated Serum Levels of Soluble TNF Receptors and Adhesion Molecules Are Associated with Diabetic Retinopathy in Patients with Type-1 DiabetesShruti Sharma, Sharad Purohit, Ashok Sharma, et al.
Diabetes Care|August 31, 2012
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trialIrl B Hirsch, Bruce Bode, Jean-Pierre Courreges, et al.
Annals of Internal Medicine|September 25, 2023
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized TrialHarpreet S Bajaj, Jens Aberle, Melanie Davies, et al.
Diabetes, Obesity & Metabolism|March 9, 2021
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2Mark Warren, Bruce Bode, Jang I Cho, et al.
Journal of Diabetes Science and Technology|April 4, 2025
Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor DesignShridhara Alva, Anuj Bhargava, Bruce Bode, et al.
The Lancet. Diabetes & Endocrinology|September 6, 2014
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetesStephen C L Gough, Bruce Bode, Vincent Woo, et al.
Diabetes Care|March 5, 2002
Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetesBruce Bode, Richard Weinstein, David Bell, et al.
The Lancet. Diabetes & Endocrinology|June 14, 2019
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trialThomas R Pieber, Bruce Bode, Ann Mertens, et al.
Lancet (London, England)|September 30, 2008
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialAlan Garber, Robert Henry, Robert Ratner, et al.
The Diabetes Educator|April 21, 2004
Patient perception and use of an insulin injector/glucose monitor combined deviceBruce Bode, John Shelmet, Brent Gooch, et al.
Pageof 7